vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PARK NATIONAL CORP (PRK). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $168.3M, roughly 1.7× PARK NATIONAL CORP). PARK NATIONAL CORP runs the higher net margin — 25.3% vs -45.7%, a 71.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 2.2%). PARK NATIONAL CORP produced more free cash flow last quarter ($191.9M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 4.9%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
GH vs PRK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $168.3M |
| Net Profit | $-128.5M | $42.6M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 25.3% |
| Revenue YoY | 39.4% | 2.2% |
| Net Profit YoY | -15.8% | 10.4% |
| EPS (diluted) | $-1.01 | $2.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $168.3M | ||
| Q3 25 | $265.2M | $169.5M | ||
| Q2 25 | $232.1M | $168.7M | ||
| Q1 25 | $203.5M | $157.9M | ||
| Q4 24 | $201.8M | $164.7M | ||
| Q3 24 | $191.5M | $170.3M | ||
| Q2 24 | $177.2M | $157.7M | ||
| Q1 24 | $168.5M | $152.8M |
| Q4 25 | $-128.5M | $42.6M | ||
| Q3 25 | $-92.7M | $47.2M | ||
| Q2 25 | $-99.9M | $48.1M | ||
| Q1 25 | $-95.2M | $42.2M | ||
| Q4 24 | $-111.0M | $38.6M | ||
| Q3 24 | $-107.8M | $38.2M | ||
| Q2 24 | $-102.6M | $39.4M | ||
| Q1 24 | $-115.0M | $35.2M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | 34.3% | ||
| Q2 25 | -45.9% | 35.2% | ||
| Q1 25 | -54.6% | 32.4% | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | 27.4% | ||
| Q2 24 | -56.8% | 30.6% | ||
| Q1 24 | -59.2% | 27.8% |
| Q4 25 | -45.7% | 25.3% | ||
| Q3 25 | -35.0% | 27.8% | ||
| Q2 25 | -43.0% | 28.5% | ||
| Q1 25 | -46.8% | 26.7% | ||
| Q4 24 | -55.0% | 23.5% | ||
| Q3 24 | -56.3% | 22.4% | ||
| Q2 24 | -57.9% | 25.0% | ||
| Q1 24 | -68.2% | 23.0% |
| Q4 25 | $-1.01 | $2.62 | ||
| Q3 25 | $-0.74 | $2.92 | ||
| Q2 25 | $-0.80 | $2.97 | ||
| Q1 25 | $-0.77 | $2.60 | ||
| Q4 24 | $-0.90 | $2.38 | ||
| Q3 24 | $-0.88 | $2.35 | ||
| Q2 24 | $-0.84 | $2.42 | ||
| Q1 24 | $-0.94 | $2.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $233.5M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.4B |
| Total Assets | $2.0B | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $233.5M | ||
| Q3 25 | $580.0M | $218.9M | ||
| Q2 25 | $629.1M | $193.1M | ||
| Q1 25 | $698.6M | $237.6M | ||
| Q4 24 | $525.5M | $160.6M | ||
| Q3 24 | $585.0M | $201.7M | ||
| Q2 24 | $933.7M | $261.5M | ||
| Q1 24 | $1.0B | $306.1M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $1.4B | ||
| Q3 25 | $-354.5M | $1.3B | ||
| Q2 25 | $-305.5M | $1.3B | ||
| Q1 25 | $-250.8M | $1.3B | ||
| Q4 24 | $-139.6M | $1.2B | ||
| Q3 24 | $-60.1M | $1.2B | ||
| Q2 24 | $-1.6M | $1.2B | ||
| Q1 24 | $68.3M | $1.2B |
| Q4 25 | $2.0B | $9.8B | ||
| Q3 25 | $1.3B | $9.9B | ||
| Q2 25 | $1.3B | $9.9B | ||
| Q1 25 | $1.3B | $9.9B | ||
| Q4 24 | $1.5B | $9.8B | ||
| Q3 24 | $1.5B | $9.9B | ||
| Q2 24 | $1.6B | $9.9B | ||
| Q1 24 | $1.7B | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $198.3M |
| Free Cash FlowOCF − Capex | $-54.2M | $191.9M |
| FCF MarginFCF / Revenue | -19.3% | 114.1% |
| Capex IntensityCapex / Revenue | 9.9% | 3.8% |
| Cash ConversionOCF / Net Profit | — | 4.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $328.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $198.3M | ||
| Q3 25 | $-35.4M | $52.6M | ||
| Q2 25 | $-60.3M | $49.7M | ||
| Q1 25 | $-62.7M | $37.9M | ||
| Q4 24 | $-64.5M | $178.8M | ||
| Q3 24 | $-51.1M | $43.8M | ||
| Q2 24 | $-94.0M | $50.9M | ||
| Q1 24 | $-30.3M | $35.0M |
| Q4 25 | $-54.2M | $191.9M | ||
| Q3 25 | $-45.8M | $51.1M | ||
| Q2 25 | $-65.9M | $48.4M | ||
| Q1 25 | $-67.1M | $36.8M | ||
| Q4 24 | $-83.4M | $169.7M | ||
| Q3 24 | $-55.3M | $41.7M | ||
| Q2 24 | $-99.1M | $49.0M | ||
| Q1 24 | $-37.2M | $31.9M |
| Q4 25 | -19.3% | 114.1% | ||
| Q3 25 | -17.3% | 30.1% | ||
| Q2 25 | -28.4% | 28.7% | ||
| Q1 25 | -33.0% | 23.3% | ||
| Q4 24 | -41.3% | 103.0% | ||
| Q3 24 | -28.9% | 24.5% | ||
| Q2 24 | -55.9% | 31.1% | ||
| Q1 24 | -22.1% | 20.8% |
| Q4 25 | 9.9% | 3.8% | ||
| Q3 25 | 3.9% | 0.9% | ||
| Q2 25 | 2.4% | 0.8% | ||
| Q1 25 | 2.2% | 0.7% | ||
| Q4 24 | 9.4% | 5.6% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 2.9% | 1.2% | ||
| Q1 24 | 4.1% | 2.1% |
| Q4 25 | — | 4.65× | ||
| Q3 25 | — | 1.11× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 4.63× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PRK
Segment breakdown not available.
